Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Gene Therapy for Longevity, Performance & Wellness
| Round | Raised | Date |
|---|---|---|
| Series 1: Amount not disclosed | — | — |
| Seed: Amount not disclosed | — | 2024-04-04 |
| Seed: Amount not disclosed | — | 2023-01-30 |
| Accelerator/Incubator: Amount not disclosed | — | 2021-01-01 |
| Seed: Amount not disclosed | — | 2019-04-01 |
Minicircle is a gene therapy platform built on non-viral plasmid DNA. It describes itself as a platform rather than a medical provider, and its therapies are given at independent partner clinics.
Source: Minicircle
Its current therapy is follistatin, marketed for lean muscle, offered through clinics in Central America. Minicircle states that its therapies are investigational and have not been reviewed by the FDA, and it lists klotho as a coming product.
Source: Minicircle
Mac Davis, the CEO, and Walter Patterson, the chief science officer, founded Minicircle. They previously worked together at Prophase Biostudios in Austin, Texas.
Source: Minicircle
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. Minicircle stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.